Clinical Trial Update: A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab in combination with sEphB4 for metastatic urothelial carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• sEphB4 (sEphB4)

Snippet

Sponsor: Vasgene Therapeutics, Inc | Conditions: Metastatic Urothelial Carcinoma | Phase 2 | Status: RECRUITING